Jaguar Health Converts Series R Preferred Shares Into Common Stock
Jaguar Health completed the conversion of its Series R preferred stock into 13,345,986 common shares. Each Series R share converted into five common shares on November 2, 2026. Eligible warrant holders may receive up to 69,823 additional common shares.
How this was made

The 30-second read
Why it matters
The dilution increases share count, likely exerting modest downward pressure on the stock price.
Market read
A primary corporate‑action disclosure with limited trading relevance beyond the ticker itself.
What to watch
Potential future financing needs or strategic moves that may follow the conversion are not disclosed.
Background
Jaguar Health announced the conversion of its Series R preferred stock into common shares, a routine corporate action disclosed via an 8‑K filing.
Ticker impact
Jaguar Health filed an 8‑K reporting the automatic conversion of each Series R preferred share into five common shares, increasing common shares to 13,345,986.
likely modest price decline as market prices in the dilution from the conversion
The filing is the first public disclosure of the conversion; dilution is a known driver of short‑term price pressure.
Market effects
Minimal impact on the broader biotech/pharma sector; the event is company‑specific.
Limited to U.S. investors holding JAGX; no broader regional effect.
Low; the conversion does not affect global markets.
Counterpoint
If the conversion unlocks liquidity for warrant holders, it could support a short‑term rally.
Key entities
- CompanyJaguar Health, Inc.
Biopharma company completing a preferred‑to‑common conversion.